Ruboxastaurin mesilate hydrate

• CAT Number: I012254
• CAS Number: 202260-21-7
• Molecular Formula: C29H34N4O7S
• Molecular Weight: 582.672
• Purity: ≥95%
• Synonyms: Arxxant; LY-333531 Mesilate; (18S)-18-[(Dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1;{7,14}.0;{2,6}.0;{8,13}.0;{22,27}]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione Mesylate Monohydrate
• InChI: InChI=1S/C28H28N4O3.CH4O3S.H2O/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;1-5(2,3)4;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H3,(H,2,3,4);1H2/t18-;;/m0../s1
• InChIKey: YTKBKIVYPITVAO-NTEVMMBTSA-N
• SMILES: CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.CS(=O)(=O)O.O

Ruboxastaurin mesilate hydrate is a selective protein kinase C (PKC) beta inhibitor that has been investigated for its potential in treating diabetic complications, particularly diabetic retinopathy. By inhibiting PKC beta, Ruboxastaurin aims to prevent the abnormal blood vessel growth and permeability associated with diabetic retinopathy, which can lead to vision loss. It has shown promise in clinical trials for reducing the progression of this condition and improving visual outcomes in patients with diabetes. However, despite positive results in some studies, its development has faced challenges, and it has not been widely adopted as a standard treatment.